F. Di Modugno

发表

The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome

M. Fassan, M. Bissell, A. Scarpa, 2016, Oncoimmunology.

3D models in the new era of immune oncology: focus on T cells, CAF and ECM

G. Ruocco, C. Colosi, P. Nisticò, 2019, Journal of Experimental & Clinical Cancer Research.

Influence of both TCR repertoire and severity of the atopic status on the cytokine secretion profile of Parietaria officinalis ‐specific T cells

Andreas Radbruch, F. Annunziato, E. Maggi, 1998, European journal of immunology.

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

P. Visca, L. Crinò, V. Ludovini, 2014, Journal of Translational Medicine.

The actin modulator hMENA regulates GAS6‐AXL axis and pro‐tumor cancer/stromal cell cooperation

P. Visca, E. Gallo, A. Scarpa, 2020, EMBO reports.

Strategies for Efficient Targeting of Tumor Collagen for Cancer Therapy

S. Baldari, P. Nisticò, F. Di Modugno, 2022, Cancers.

Host immunosurveillance contributes to the control of erbB‐2 overexpression in HLA‐A2‐breast‐cancer patients

M. Mottolese, P. Natali, S. Cascioli, 1999, International journal of cancer.

β1 and β4 integrins: from breast development to clinical practice

M. Bissell, P. Nisticò, F. Di Modugno, 2014, Breast Cancer Research.

Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology

P. Nisticò, F. Di Modugno, S. Spada, 2021, Journal of experimental & clinical cancer research : CR.

Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors

R. Carstens, M. Bissell, M. Mottolese, 2012, Proceedings of the National Academy of Sciences.

Human Mena+11a Isoform Serves as a Marker of Epithelial Phenotype and Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Pancreatic Cancer Cell Lines

U. Philippar, M. Pino, D. McConkey, 2008, Clinical Cancer Research.

The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors

M. Mottolese, A. Santoni, P. Natali, 2006, Clinical Cancer Research.

Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines.

J. Condeelis, M. Alessio, A. Santoni, 2007, Cancer research.

Human mena protein, a serex‐defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T‐cell immune response

M. Mottolese, A. Santoni, P. Natali, 2004, International journal of cancer.

hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis

M. Bissell, P. Visca, E. Chen, 2018, Oncogene.

Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting.

G. Manic, A. Sistigu, P. Nisticò, 2017, Cytokine & growth factor reviews.

Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis

C. Riganti, M. Capello, F. Novelli, 2017, Journal of Hematology & Oncology.

The Cooperation between hMena Overexpression and HER2 Signalling in Breast Cancer

M. Mottolese, M. Alessio, A. Santoni, 2010, PloS one.

Polyclonal Antibodies Against gp185HER2 Peptides: Their Putative Role in the Identification of a Particular HER2 Status in Patients With Breast Cancer

M. Mottolese, A. Santoni, S. Buglioni, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Selective 'in synthesis' labelling of peptides by fluorochromes.

F. Di Modugno, L. Rosanò, A. Chersi, 1997, Biochimica et biophysica acta.

3D models in the new era of immune oncology: focus on T cells, CAF and ECM

G. Ruocco, C. Colosi, P. Nisticò, 2019, Journal of experimental & clinical cancer research : CR.

Molecular and genetic bases of pancreatic cancer.

M. Pino, M. Milella, F. Cognetti, 2012, Current Drug Targets.

Interferon‐gamma (IFN‐γ) can counteract the in vitro inhibitory effect of an HIV p24 immunosuppressive heptapeptide

E. Giacomini, F. Di Modugno, M. Boirivant, 1996, Clinical and experimental immunology.

Aims and limitations in the use of antipeptide antibodies in molecular biology.

F. Di Modugno, L. Rosanò, A. Chersi, 1997, Biological chemistry.

hMENA is a key regulator in endothelin-1/β-arrestin1–induced invadopodial function and metastatic process

G. Blandino, A. Sacconi, G. Ferrandina, 2018, Proceedings of the National Academy of Sciences.

hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC

F. Cappuzzo, P. Visca, C. Tripodo, 2023, Journal for ImmunoTherapy of Cancer.

hMENA11a, a hMENA isoform sending survival signals

P. Nisticò, F. Di Modugno, P. Trono, 2015, Molecular & Cellular Oncology.

hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis

M. Bissell, P. Visca, E. Chen, 2018, Oncogene.

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

P. Visca, L. Crinò, V. Ludovini, 2014, Journal of Translational Medicine.

Transcription factors in fibroblast plasticity and CAF heterogeneity

P. Nisticò, F. Di Modugno, A. D. Di Carlo, 2023, Journal of experimental & clinical cancer research : CR.